Fresh Insights On Ambrx Biopharma Inc. (AMAM)

Ambrx Biopharma Inc. (NASDAQ:AMAM) concluded the trading at $9.30 on Friday, September 15 with a fall of -6.44% from its closing price on previous day.

Taking a look at stock we notice that its last check on previous day was $9.94 and 5Y monthly beta was reading -2.68 with its price kept floating in the range of $8.328 and $9.765 on the day. Considering stock’s 52-week price range provides that AMAM hit a high price of $16.86 and saw its price falling to a low level of $0.38 during that period. Over a period of past 1-month, stock came subtracting -29.81% in its value.

With its current market valuation of $604.04 million. Analysts are in estimates of -$0.09 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -$0.51 for 2023 with estimates of that growing to -$0.5 in next year. These estimates are suggesting current year growth of 74.90% for EPS and 2.00% growth next year.

Analysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of $1 million. In keeping analyst consensus estimate with, company is forecasted to be making an annual revenue of $3.23 million in 2023, which will be -56.40% less from revenue generated by the company last year.

In last 7 days, analysts came adjusting their opinions about stock’s EPS with no upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In contrast, when we review AMAM stock’s current outlook then short term indicators are assigning it an average of 50% Sell, while medium term indicators are categorizing the stock at an average of 50% Buy. Long term indicators are suggesting an average of 50% Sell for it.

Digging deeper we become aware of the PEG ratio of the AMAM stock which is currently positioned at 0. It further provides that stock’s current price level is -29.34% away from its 20-day simple moving average and is -34.01% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 20.15 while volatility remained at 10.47% over the past week which changes to 7.73% when measuring it over the past month. Beta is valued at -2.65, while measure of average true range or ATR is currently at 0.95.

In comparing Ambrx Biopharma Inc. (AMAM)’s stock with other industry players reveals that stock’s current price change of -6.44% and that of 638.10% over the past 12 months. Industry’s another major player Rogers Corporation (ROG) has rise 1.52% up in previous session, but over the past year has faced a fall of -44.60%, while AstraZeneca PLC (AZN) was also up 0.72% however its price remained floating in the green at 16.26% over the same period. Ambrx Biopharma Inc. has a P/E ratio of 0 while Rogers Corporation is showing 27.45 for the same. On the other hand, the S&P 500 Index was down -1.22% in the last trading session while the Dow Jones Industrial closed the session lower at -0.83%.

Having a second look at Ambrx Biopharma Inc. (NASDAQ:AMAM) provides that stock’s average daily trading volume for 3 months was 317.97K, while it jumped to 0.45 million when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 55.90 million.

The percentage of outstanding shares held by the insiders is 25.38% while it is 49.90% for the institutional holders. The figures also indicate that as of Aug 30, 2023, number of stock’s short shares was 0.78 million which implies a short ratio of 2.69. This shows down a 1.26% of Short Interest in company’s outstanding shares on the day. In August the standing of shares short improved as it was 0.82 million in the previous month. Addition of 309.69% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.